Iridium is a key component in many electrochemical technologies used for chemical transformations. These include producing ...
Precious metals, serving as catalysts, are the backbone of many materials industries, but a new form of aluminum could be set to replace them.
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors Chronic myelomonocytic leukemia ...
- In a head-to-head cyclic adenosine monophosphate (cAMP) activation assay vs. eloralintide, oral small molecule amylin receptor agonist ASC39 demonstrated similar selectivity and potency to that of ...
To build a self-supervised magnetic resonance imaging (MRI) foundation model from routine clinical scans and to test whether it can support key glioma-related applications, including post-therapy ...
AlphaGenome is a leap forward in the ability to study the human blueprint. But the fine workings of our DNA are still largely a mystery. By Carl Zimmer In 2024, two scientists from Google DeepMind ...
Royalty-free licenses let you pay once to use copyrighted images and video clips in personal and commercial projects on an ongoing basis without requiring additional payments each time you use that ...
Two teenage founders walked into Y Combinator co-founder Paul Graham’s backyard with an idea no one in agriculture seemed to want — an AI model to help design better pesticides. By the time they left, ...
Brown dwarfs: too small to be stars, too big to be planets. Only discovered in the 1990s, these in-between cosmic objects aren’t big enough to burn as hot and bright as a true star, instead usually ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...
Abstract: Molecular communication (MC) research is increasingly focused on applications within the human body, such as health monitoring and drug delivery, which require testing in realistic and ...
This process is costly, time-consuming, and has a low success rate. KAIST researchers have developed an AI model that, using only information about the target protein, can design optimal drug ...